T.Man Pharmaceutical PCL (BKK:TMAN)
Thailand · Delayed Price · Currency is THB 11.20
0.00 (0.00%)
At close: Jun 2, 2026
T.Man Pharmaceutical PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,506 | 2,213 | 1,972 | 2,017 | 1,260 |
Other Revenue | 19.94 | 13.35 | 7.81 | 8.05 | 3.43 |
| 2,526 | 2,226 | 1,980 | 2,025 | 1,263 | |
Revenue Growth (YoY) | 13.48% | 12.42% | -2.20% | 60.26% | 40.25% |
Cost of Revenue | 1,338 | 1,133 | 1,003 | 923.57 | 861.26 |
Gross Profit | 1,188 | 1,093 | 976.84 | 1,101 | 402.08 |
Selling, General & Admin | 597.11 | 546.65 | 496.43 | 452.32 | 313.35 |
Operating Expenses | 603.04 | 543.35 | 451.8 | 492.88 | 321.07 |
Operating Income | 584.79 | 549.98 | 525.04 | 608.21 | 81.01 |
Interest Expense | -28.44 | -18.63 | -14.85 | -16.98 | -7.18 |
EBT Excluding Unusual Items | 556.35 | 531.36 | 510.19 | 591.23 | 73.83 |
Other Unusual Items | -107.06 | - | - | - | - |
Pretax Income | 613.81 | 531.36 | 510.19 | 591.23 | 73.83 |
Income Tax Expense | 90.74 | 80.65 | 79.1 | 118.71 | 17.44 |
Earnings From Continuing Operations | 523.07 | 450.7 | 431.09 | 472.52 | 56.39 |
Minority Interest in Earnings | -0 | -0 | -0 | - | - |
Net Income | 523.07 | 450.7 | 431.09 | 472.52 | 56.39 |
Net Income to Common | 523.07 | 450.7 | 431.09 | 472.52 | 56.39 |
Net Income Growth | 16.06% | 4.55% | -8.77% | 737.91% | -5.84% |
Shares Outstanding (Basic) | 400 | 343 | 275 | 250 | 72 |
Shares Outstanding (Diluted) | 400 | 343 | 275 | 250 | 72 |
Shares Change (YoY) | 16.47% | 24.68% | 10.30% | 246.21% | 8.20% |
EPS (Basic) | 1.31 | 1.31 | 1.56 | 1.89 | 0.78 |
EPS (Diluted) | 1.31 | 1.31 | 1.56 | 1.89 | 0.78 |
EPS Growth | -0.35% | -16.14% | -17.29% | 142.02% | -12.98% |
Free Cash Flow | 110 | 345.71 | 62.15 | 289.02 | 196.49 |
Free Cash Flow Per Share | 0.28 | 1.01 | 0.23 | 1.16 | 2.72 |
Dividend Per Share | 0.320 | 0.200 | 0.036 | - | - |
Dividend Growth | 60.00% | 455.56% | - | - | - |
Gross Margin | 47.02% | 49.12% | 49.33% | 54.38% | 31.83% |
Operating Margin | 23.15% | 24.71% | 26.52% | 30.04% | 6.41% |
Profit Margin | 20.71% | 20.25% | 21.77% | 23.34% | 4.46% |
Free Cash Flow Margin | 4.35% | 15.53% | 3.14% | 14.27% | 15.55% |
EBITDA | 700.72 | 645.11 | 611.56 | 678.68 | 148.29 |
EBITDA Margin | 27.74% | 28.98% | 30.89% | 33.52% | 11.74% |
D&A For EBITDA | 115.93 | 95.12 | 86.52 | 70.48 | 67.28 |
EBIT | 584.79 | 549.98 | 525.04 | 608.21 | 81.01 |
EBIT Margin | 23.15% | 24.71% | 26.52% | 30.04% | 6.41% |
Effective Tax Rate | 14.78% | 15.18% | 15.50% | 20.08% | 23.62% |
Revenue as Reported | 2,691 | 2,226 | 1,980 | 2,025 | 1,263 |
Advertising Expenses | 101 | 113 | 97 | 89 | 52 |